The U.S. Securities and Exchange Commission has proposed new rules and amendments (the Proposed Rules) to enhance disclosure and expand liability in initial public offerings by special purpose acquisition companies (SPACs)...more
4/7/2022
/ Comment Period ,
Corporate Governance ,
Disclosure Requirements ,
Enforcement ,
Financial Statements ,
Initial Public Offering (IPO) ,
Investors ,
Liability ,
Proposed Amendments ,
Proposed Rules ,
PSLRA ,
Publicly-Traded Companies ,
Securities and Exchange Commission (SEC) ,
Shareholder Meetings ,
Smaller Reporting Companies ,
Special Purpose Acquisition Companies (SPACs) ,
Target Company
The rise of special purpose acquisition companies (SPACs) as a popular alternative structure for taking a company public in the past year has caused increased regulatory scrutiny surrounding the SPAC structure. On May 24,...more
5/24/2021
/ Acquisitions ,
Due Diligence ,
Financial Adviser ,
Mergers ,
Proposed Legislation ,
Publicly-Traded Companies ,
Safe Harbors ,
Securities Act of 1933 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Securities Litigation ,
Special Purpose Acquisition Companies (SPACs)
John Coates, Acting Director of the Division of Corporation Finance at the U.S. Securities and Exchange Commission (SEC), issued a public statement providing insight into the SEC’s views on the application of federal...more
4/12/2021
/ D&O Insurance ,
Due Diligence ,
Financial Adviser ,
Initial Public Offering (IPO) ,
New Guidance ,
Privately Held Corporations ,
PSLRA ,
Safe Harbors ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Special Purpose Acquisition Companies (SPACs)
On December 22, 2020, in litigation between WeWork and the Softbank Group, the Delaware Court of Chancery determined that the Softbank Group must hand over several dozen otherwise privileged emails because two SoftBank...more
Special purpose acquisition companies (SPACs) are increasingly being used as an alternate vehicle to traditional initial public offerings. Companies that go public through a traditional IPO process are often subject to...more
On Friday, September 19, 2014, a Chinese court found pharmaceutical giant GlaxoSmithKline guilty of bribing doctors and hospitals in order to increase sales of the company’s products in China. Among other things, the company...more